Phaseline

Companies › EIR Biotherapies s.r.l.

EIR Biotherapies s.r.l.: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RR001
Cell-based gene therapy
–Phase 1Locally Advanced Pancreatic AdenocarcinomaJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06861452RR001Phase 1Locally Advanced Pancreatic AdenocarcinomaOncologyJul 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.